Abstract
The traditional agents used for thromboprophylaxis are effective and safe but have limitations particularly related to ease of administration. Newer agents targeting single coagulation factors such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban and apixaban have demonstrated efficacy and safety for thromboembolism prophylaxis in the orthopedic population and have the additional benefit of oral administration and predictable pharmacokinetics. Pharmacology of the new anticoagulants and published data on the use of these agents in total knee and hip replacement patients will be reviewed in this article.
Keywords: Thromboprophylaxis, dabigatran, rivaroxaban, apixaban, Anticoagulants, Thromboembolism, Venous thromboembolism, low molecular, synthetic pentasaccharide, vitamin K antagonists, warfarin, narrow therapeutic index, multiple drug, DABIGATRAN ETEXILATE, quinine, verapamil, total hip replacement, total knee replacement, RE-NOVATE, creatinine, enoxaparin, nonfatal PE, proximal DVT, factor Xa, VTE prophylaxis, thrombin inhibitor, hip arthroplasty, pharmacokinetics, knee replacement
Current Pharmaceutical Design
Title: New Anticoagulants for the Prevention of Thromboembolism
Volume: 16 Issue: 31
Author(s): Kylie Lepic and Mark Crowther
Affiliation:
Keywords: Thromboprophylaxis, dabigatran, rivaroxaban, apixaban, Anticoagulants, Thromboembolism, Venous thromboembolism, low molecular, synthetic pentasaccharide, vitamin K antagonists, warfarin, narrow therapeutic index, multiple drug, DABIGATRAN ETEXILATE, quinine, verapamil, total hip replacement, total knee replacement, RE-NOVATE, creatinine, enoxaparin, nonfatal PE, proximal DVT, factor Xa, VTE prophylaxis, thrombin inhibitor, hip arthroplasty, pharmacokinetics, knee replacement
Abstract: The traditional agents used for thromboprophylaxis are effective and safe but have limitations particularly related to ease of administration. Newer agents targeting single coagulation factors such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban and apixaban have demonstrated efficacy and safety for thromboembolism prophylaxis in the orthopedic population and have the additional benefit of oral administration and predictable pharmacokinetics. Pharmacology of the new anticoagulants and published data on the use of these agents in total knee and hip replacement patients will be reviewed in this article.
Export Options
About this article
Cite this article as:
Lepic Kylie and Crowther Mark, New Anticoagulants for the Prevention of Thromboembolism, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563437
DOI https://dx.doi.org/10.2174/138161210793563437 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Fatty Acid Metabolism in the Treatments of Obesity and Disorders of CNS Cellular Energy Balance
Central Nervous System Agents in Medicinal Chemistry Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
Current Molecular Medicine Meet Our Regional Editor
Current Vascular Pharmacology Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia
Recent Patents on DNA & Gene Sequences Plasma Potassium Levels in Healthy Prehypertension Subjects and the Role of A High Potassium Drink
Current Hypertension Reviews Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) Structural and Functional MRI in Mild Cognitive Impairment
Current Alzheimer Research The SAMP8 Mouse: A Model to Develop Therapeutic Interventions for Alzheimers Disease
Current Pharmaceutical Design Medication Non-adherence in Patients with Osteoporosis: Implications for Clinical Pharmacists and Osteoporosis Care Providers
Current Clinical Pharmacology Poly(ε-caprolactone) Films with Favourable Properties for Neural Cell Growth
Current Topics in Medicinal Chemistry Buxus sempervirens L Improves Streptozotocin-induced Diabetes Mellitus in Rats
Cardiovascular & Hematological Disorders-Drug Targets Insights into Cholesterol Efflux in Vascular Endothelial Cells
Cardiovascular & Hematological Disorders-Drug Targets The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design Extracellular Matrix Remodeling in Hypertension
Current Hypertension Reviews Sleep Disordered Breathing: Alternatives to CPAP Therapy
Current Respiratory Medicine Reviews Recent Development in the Search for Effective Antidepressants Using Traditional Chinese Medicine
Central Nervous System Agents in Medicinal Chemistry Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships
Current Medicinal Chemistry Effects of Coenzyme Q and Creatine Supplementation on Brain Energy Metabolism in Rats Exposed to Chronic Cerebral Hypoperfusion
Current Alzheimer Research